JP2018527895A - 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法 - Google Patents

抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法 Download PDF

Info

Publication number
JP2018527895A
JP2018527895A JP2017568233A JP2017568233A JP2018527895A JP 2018527895 A JP2018527895 A JP 2018527895A JP 2017568233 A JP2017568233 A JP 2017568233A JP 2017568233 A JP2017568233 A JP 2017568233A JP 2018527895 A JP2018527895 A JP 2018527895A
Authority
JP
Japan
Prior art keywords
seq
monoclonal antibody
cell line
hybridoma cell
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017568233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527895A5 (https=
Inventor
エス．ハリス ルーベン
エス．ハリス ルーベン
ブラウン ウィリアム
ブラウン ウィリアム
カーペンター マイケル
カーペンター マイケル
ロー エミリー
ロー エミリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of JP2018527895A publication Critical patent/JP2018527895A/ja
Publication of JP2018527895A5 publication Critical patent/JP2018527895A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017568233A 2015-06-29 2016-06-29 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法 Pending JP2018527895A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186109P 2015-06-29 2015-06-29
US62/186,109 2015-06-29
PCT/US2016/040011 WO2017004151A1 (en) 2015-06-29 2016-06-29 Anti-apobec3 antibodies and methods of making and using

Publications (2)

Publication Number Publication Date
JP2018527895A true JP2018527895A (ja) 2018-09-27
JP2018527895A5 JP2018527895A5 (https=) 2019-08-22

Family

ID=57609413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017568233A Pending JP2018527895A (ja) 2015-06-29 2016-06-29 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法

Country Status (4)

Country Link
US (1) US10752699B2 (https=)
EP (1) EP3313993A4 (https=)
JP (1) JP2018527895A (https=)
WO (1) WO2017004151A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018527895A (ja) 2015-06-29 2018-09-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法
US11891439B2 (en) 2017-12-28 2024-02-06 Astute Medical, Inc. Antibodies and assays for CCL14
EP3938522A4 (en) * 2019-03-15 2023-01-11 Mayo Foundation for Medical Education and Research ONCOLYTIC VIRUSES AND METHODS OF USE OF ONCOLYTIC VIRUSES
CA3145667A1 (en) * 2019-07-02 2021-01-07 Astute Medical, Inc Antibodies and assays for ccl14
US12600778B2 (en) 2019-10-31 2026-04-14 The Research Foundation For The State University Of New York Rage antibodies, fragments and uses thereof
CA3231704A1 (en) * 2021-09-13 2023-03-16 The Board Of Regents Of The University Of Texas System Trem2 antigen binding proteins and uses thereof
CN117802095B (zh) * 2024-03-01 2024-06-25 广东工业大学 一种检测核酸胞嘧啶脱氨酶apobec3b活性的化学发光试剂盒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521711A (ja) * 2013-06-10 2016-07-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｍｖ中和抗原結合性タンパク質

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2195297A (en) 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
US20110111424A1 (en) * 2001-06-21 2011-05-12 Cell Signaling Technology, Inc. Analysis of ubiquitinated polypeptides
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
ATE506456T1 (de) 2003-06-10 2011-05-15 David Gladstone Inst Verfahren zur behandlung von lentivirusinfektionen
US8133666B2 (en) 2004-11-02 2012-03-13 The J. David Gladstone Institutes Method for identifying agents capable of inhibiting APOBEC3C activity in HIV-infected cells
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
WO2007146977A1 (en) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
EP2036988A1 (en) 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
WO2010039223A2 (en) * 2008-09-30 2010-04-08 The Regents Of The University Of California T-cell immunogens derived from anti-viral proteins and methods of using same
US20120252026A1 (en) 2011-04-01 2012-10-04 Harris Reuben S Cancer biomarker, diagnostic methods, and assay reagents
JP6215235B2 (ja) 2012-01-24 2017-10-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌の治療方法
US20150111836A1 (en) 2012-02-12 2015-04-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cellular apobec3 proteins and modulators thereof for regulating dna repair processes and treating proliferative diseases
EP3626309B1 (en) 2012-08-13 2023-03-08 The Rockefeller University Lxrbeta agonist for the treatment of cancer
HU230680B1 (hu) 2012-10-19 2017-08-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Diagnosztikai eljárás
EP3041859A2 (en) 2013-09-03 2016-07-13 INSERM - Institut National de la Santé et de la Recherche Médicale Compositions and methods for inducing senescence in cancer cells
DK3169341T3 (da) 2014-07-16 2019-08-05 Transgene Sa Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
AU2015289081B2 (en) 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
GB201420859D0 (en) 2014-11-24 2015-01-07 Cancer Res Inst Royal Tumour analysis
JP2018527895A (ja) 2015-06-29 2018-09-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法
US20200046671A1 (en) 2015-06-29 2020-02-13 Regents Of The University Of Minnesota Apobec3b mutagenesis and immunotherapy
US20180185302A1 (en) 2015-06-30 2018-07-05 Regents Of The University Of Minnesota Methods for downregulating apobec3b
WO2017165629A1 (en) 2016-03-23 2017-09-28 Regents Of The University Of Minnesota Methods of detecting apobec3 expression and predicting clinical outcomes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521711A (ja) * 2013-06-10 2016-07-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｍｖ中和抗原結合性タンパク質

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAN, Y. ET AL: "APOBEC3G and APOBEC3F Require an Endogenous Cofactor to Block HIV-1 Replication", PLOS PATHOGENS, vol. Volume 4, Issue 7, JPN6020020693, 2008, pages 1000095, ISSN: 0004439911 *
JIN, Z. ET AL: "The role of APOBEC3B in chondrosarcoma", ONCOLOGY REPORTS, vol. 32, JPN6020020692, 2014, pages 1867 - 1872, ISSN: 0004439912 *
LEENAARS, M. ET AL: "Critical Steps in the Production of Polyclonal and Monoclonal Antibodies: Evaluation and Recommendat", ILAR JOURNAL, vol. Volume 46, Number 3, JPN6020020694, 2005, pages 269 - 279, ISSN: 0004439913 *

Also Published As

Publication number Publication date
US10752699B2 (en) 2020-08-25
EP3313993A4 (en) 2019-06-19
WO2017004151A1 (en) 2017-01-05
US20180171029A1 (en) 2018-06-21
EP3313993A1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
US10752699B2 (en) Anti-APOBEC3 antibodies and methods of making and using
US9371396B2 (en) Anti-CD22 anti-idiotypic antibodies and uses thereof
TWI655209B (zh) 結合人類計畫性死亡（ｐｒｏｇｒａｍｍｅｄ ｄｅａｔｈ）配位子１（ｐｄ－ｌ１）之抗體
JP5941615B2 (ja) ヒトｃｘｃｌ１タンパク質の免疫学的測定方法
US8114634B2 (en) Methods, systems and reagents for improved immunodetection
US9403913B2 (en) Anti-VASA antibodies, and methods of production and use thereof
US20220073611A1 (en) Anti-nmda receptor antibodies and methods of use
CN113150138A (zh) 一种kpc-2单克隆抗体及其制备方法和应用
US10577418B2 (en) Monoclonal anti-GPC-1 antibodies and uses thereof
CN112250767A (zh) 一种结合Strep-Tag II标签的抗体及其应用
CN114578066B (zh) 检测β-淀粉样蛋白的产品和方法
WO2025102711A1 (zh) 疟原虫结合蛋白及其组合与应用
CN120225680A (zh) 针对外被体蛋白复合物亚基β2的抗体
CN111434686B (zh) 一种抗人pbx1单克隆抗体，其制备方法及其在复发性流产临床诊断中的用途
CN115141275A (zh) 一种fzd7鼠源单克隆抗体及其制备方法和应用
CN119390834B (zh) 靶向IV型胶原蛋白α5链的抗体或其抗原结合片段
US20260102488A1 (en) Epitope of epb41l5, and monoclonal antibody
JP2017057198A (ja) Ｃｄ８１ ｌｅｌ特異的モノクローナル抗体
WO2024229245A9 (en) High throughput fab antibody fragment generation and ranking
WO2025061149A1 (zh) 抗gcc抗体、嵌合抗原受体及其用途
HK40106072A (zh) 特异性结合IGGκ型轻链的抗体或其结合片段及应用
WO2024157993A1 (ja) シアル酸修飾ｏ－結合型糖鎖を有するディスアドヘリンに特異的に結合する抗体
WO2023168447A2 (en) Monoclonal antibodies for detecting kawasaki disease antigens
JP2014185113A (ja) 核膜孔タンパク質Ｎｕｐ９８を特異的に認識するモノクローナル抗体
CN120399081A (zh) 靶向gpc3的抗体及其应用

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210209